• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

以CALR阳性原发性血小板增多症为前驱的浸润性导管乳腺癌。

Invasive ductal breast carcinoma preceded by CALR-positive essential thrombocythemia.

作者信息

Ali Elrazi A, Elmalik Hind, Omar Nabil E, Yassin Mohamed A

机构信息

Internal Medicine Department Hamad Medical Corporation Doha Qatar.

Medical Oncology and Hematology Department Hamad Medical Corporation Doha Qatar.

出版信息

Clin Case Rep. 2021 Feb 9;9(3):1732-1736. doi: 10.1002/ccr3.3892. eCollection 2021 Mar.

DOI:10.1002/ccr3.3892
PMID:33768925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7981762/
Abstract

Persistent thrombocytosis in patients with cancer needs workup because it can be linked to essential thrombocytosis. The management should be individualized to start treatment for low-risk essential thrombocytosis due to the combined risk of thrombosis.

摘要

癌症患者持续性血小板增多症需要进行检查，因为它可能与原发性血小板增多症有关。由于存在血栓形成的综合风险，对于低风险原发性血小板增多症的治疗管理应个体化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e54/7981762/f2e954f2009d/CCR3-9-1732-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e54/7981762/f2e954f2009d/CCR3-9-1732-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e54/7981762/f2e954f2009d/CCR3-9-1732-g002.jpg

相似文献

1
Invasive ductal breast carcinoma preceded by CALR-positive essential thrombocythemia.以CALR阳性原发性血小板增多症为前驱的浸润性导管乳腺癌。
Clin Case Rep. 2021 Feb 9;9(3):1732-1736. doi: 10.1002/ccr3.3892. eCollection 2021 Mar.
2
A rare CALR variant mutation and a review of CALR in essential thrombocythemia.CALR 罕见变异突变及 CALR 在原发性血小板增多症中的作用综述
J Thromb Thrombolysis. 2018 Apr;45(3):457-462. doi: 10.1007/s11239-018-1619-0.
3
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.CALR 突变的低风险原发性血小板增多症患者抗血小板治疗与观察对比
Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12.
4
A Novel Pathogenic CALR Exon 9 Mutation in a Patient with Essential Thrombocythemia.一名原发性血小板增多症患者中一种新的致病性CALR外显子9突变
Lab Med. 2020 May 6;51(3):306-309. doi: 10.1093/labmed/lmz064.
5
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.真性红细胞增多症和原发性血小板增多症：2015 年诊断、风险分层和治疗更新。
Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895.
6
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.JAK2 或 CALR 突变状态定义了具有显著不同临床过程和结局的特发性血小板增多症亚型。
Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.
7
Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2).心肌梗死作为伴有钙网蛋白（CALR）突变（非1型，非2型）的原发性血小板增多症的首发表现。
Cureus. 2023 Jan 10;15(1):e33612. doi: 10.7759/cureus.33612. eCollection 2023 Jan.
8
Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage.突变钙网织蛋白敲入小鼠在没有干细胞自我更新优势的情况下发展为血小板增多症和骨髓纤维化。
Blood. 2018 Feb 8;131(6):649-661. doi: 10.1182/blood-2017-09-806356. Epub 2017 Dec 27.
9
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.一千例原发性血小板增多症患者：佛罗伦萨-CRIMM 研究经验。
Blood Cancer J. 2024 Jan 18;14(1):10. doi: 10.1038/s41408-023-00968-7.
10
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.伴有CALR或JAK2突变的原发性血小板增多症的表型与预后分析。
Haematologica. 2015 Jul;100(7):893-7. doi: 10.3324/haematol.2014.118299. Epub 2015 May 1.

本文引用的文献

1
MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.MERGE：亚洲、中东、土耳其和阿尔及利亚的骨髓增殖性肿瘤多国多中心观察性注册研究。
Cancer Med. 2020 Jul;9(13):4512-4526. doi: 10.1002/cam4.3004. Epub 2020 Apr 30.
2
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.评估既往接受紫杉类/曲妥珠单抗治疗的、不可切除或转移性人表皮生长因子受体 2（HER2）阳性乳腺癌患者中，不同 HER2 靶向方案的临床疗效和安全性：系统评价和网络荟萃分析。
Breast Cancer Res Treat. 2020 Apr;180(3):597-609. doi: 10.1007/s10549-020-05577-7. Epub 2020 Feb 25.
3
Clinical Exome Sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: A pilot study in patients from the state of Qatar.临床外显子组测序揭示骨髓增殖性肿瘤中的新致病突变：来自卡塔尔的患者的一项试点研究。
Gene. 2019 Mar 20;689:34-42. doi: 10.1016/j.gene.2018.12.009. Epub 2018 Dec 13.
4
Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges.并存的乳腺癌和原发性血小板增多症：我们如何应对治疗挑战。
Case Rep Hematol. 2018 Aug 12;2018:2080185. doi: 10.1155/2018/2080185. eCollection 2018.
5
Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.骨髓增殖性肿瘤患者的二次恶性肿瘤：一项基于人群的 9379 例患者的队列研究。
Leukemia. 2018 Oct;32(10):2203-2210. doi: 10.1038/s41375-018-0027-y. Epub 2018 Jan 30.
6
Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study.基于人群的队列研究：乳腺癌患者静脉血栓栓塞的时间依赖性风险和预测因素。
Cancer. 2017 Feb 1;123(3):468-475. doi: 10.1002/cncr.30364. Epub 2016 Oct 11.
7
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
8
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.基于1019例世界卫生组织定义的原发性血小板增多症患者对IPSET血栓形成进行与实践相关的修订。
Blood Cancer J. 2015 Nov 27;5(11):e369. doi: 10.1038/bcj.2015.94.
9
Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.原发性血小板增多症和真性红细胞增多症患者的继发性实体瘤和淋巴瘤——单中心经验
Leuk Lymphoma. 2016;57(1):237-9. doi: 10.3109/10428194.2015.1041392. Epub 2015 Sep 25.
10
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.钙网蛋白突变不会改变1150例原发性血小板增多症患者中用于预测血栓形成风险的IPSET评分。
Blood. 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676.